Why the study?
The study was conducted to investigate the prognostic value of selected biomarkers in patients undergoing valve surgery.
Do selected biomarkers (hs-CRP, RDW, RBC count) predict major adverse events in patients undergoing elective valve surgery?
Do selected biomarkers (hs-CRP, RDW, RBC count) predict major adverse events in patients undergoing elective valve surgery?
Elevated high-sensitivity C-reactive protein, red cell distribution width, and red blood cell count are independent predictors of 30-day major adverse events following elective valve surgery.
Biomarkers may refine 30-day risk estimates after valve surgery; leaves open incremental value beyond clinical models in validation studies.
AIM: The aim of the study was to investigate the prognostic value of selected biomarkers in patients undergoing valve surgery. MATERIALS & METHODS: A prospective study was conducted on a group of consecutive patients with hemodynamically significant valve defects that underwent elective valve repair or replacement surgery. The primary end point was any major adverse event including death within 30 days. RESULTS: The study group included 416 patients. The composite end point occurred in 81 patients. At multivariate analysis high-sensitivity C-reactive protein (p = 0.03), red cell distribution width (p = 0.0001) and red blood cell count (p = 0.005) remained independent predictors of the primary end point. CONCLUSION: Elevated high-sensitivity C-reactive protein, red cell distribution width and red blood cell count were associated with a poorer outcome following valve surgery.
No takes yet. Share an insight, caveat, or question.
Duchnowski et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: